Your browser doesn't support javascript.
loading
Population pharmacokinetic analysis of sifalimumab from a clinical phase IIb trial in systemic lupus erythematosus patients.
Zheng, Bo; Yu, Xiang-Qing; Greth, Warren; Robbie, Gabriel J.
Affiliation
  • Zheng B; Clinical Pharmacology and DMPK (CPD), MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland, 20878.
  • Yu XQ; Clinical Pharmacology and DMPK (CPD), MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland, 20878.
  • Greth W; Clinical Development, MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland, 20878, USA.
  • Robbie GJ; Clinical Pharmacology and DMPK (CPD), MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland, 20878.
Br J Clin Pharmacol ; 81(5): 918-28, 2016 May.
Article in En | MEDLINE | ID: mdl-26659791
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lupus Erythematosus, Systemic / Antibodies, Monoclonal Type of study: Clinical_trials / Prognostic_studies Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Br J Clin Pharmacol Year: 2016 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lupus Erythematosus, Systemic / Antibodies, Monoclonal Type of study: Clinical_trials / Prognostic_studies Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Br J Clin Pharmacol Year: 2016 Document type: Article